Analysis of CGRP monoclonal antibody prescribing patterns reveals real-world usage trends, treatment sequences, and adherence in migraine prevention.
Key findingAnalysis of CGRP monoclonal antibody prescribing patterns reveals real-world usage trends, treatment
What the researchers found
Analysis of CGRP monoclonal antibody prescribing patterns reveals real-world usage trends, treatment sequences, and adherence in migraine prevention.
Why it matters
Relevant to peptide therapeutics.
How the study worked
In publication.
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Patterns of calcitonin gene-related peptide monoclonal antibody use in people with migraine: Results of the OVERCOME (US) study.
Cephalalgia : an international journal of headache, 45(6), 3331024251341243
Citation
Ashina, Sait; Kim, Gilwan; Muenzel, E Jolanda; Buse, Dawn C; Zagar, Anthony J; Zakharyan, Armen; Shapiro, Robert E; Nicholson, Robert A; Pearlman, Eric M; Lipton, Richard B. (2025). Patterns of calcitonin gene-related peptide monoclonal antibody use in people with migraine: Results of the OVERCOME (US) study.. Cephalalgia : an international journal of headache, 45(6), 3331024251341243. https://doi.org/10.1177/03331024251341243